

# Umut Kalyoncu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1019074/publications.pdf>

Version: 2024-02-01

92  
papers

1,381  
citations

394421

19  
h-index

377865

34  
g-index

93  
all docs

93  
docs citations

93  
times ranked

1834  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. <i>Clinical Rheumatology</i> , 2022, 41, 85-94.	2.2	4
2	Anxiety levels before biologic initiation and changes with treatment in patients with psoriatic arthritis: HUR-BIO biologic registry results. <i>Clinical Rheumatology</i> , 2022, , 1.	2.2	1
3	Disease activity at the entheses and joints are correlated in psoriatic arthritis when explored with ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 44-48.	0.8	3
4	Comparison of cardiovascular, cancer and herpes zoster risk of tofacitinib versus etanercept: single-centre observational study. <i>Rheumatology</i> , 2022, 61, e267-e269.	1.9	5
5	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.8	0
6	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. <i>Rheumatology International</i> , 2022, 42, 1797-1806.	3.0	0
7	The reliability, validity, and responsiveness of Cognitive Exercise Therapy Approach: Biopsychosocial Questionnaire for patients with psoriatic arthritis. <i>Rheumatology International</i> , 2022, 42, 1973-1981.	3.0	2
8	Predictors of persistent inflammation in familial Mediterranean fever and association with damage. <i>Rheumatology</i> , 2021, 60, 333-339.	1.9	21
9	PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1755-1762.	1.9	4
10	The frequency of Achilles and plantar calcaneal spurs in gout patients. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1841-1848.	0.9	2
11	Appendectomy history is associated with severe disease and colchicine resistance in adult familial Mediterranean fever patients. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1706-1711.	0.9	1
12	Phenotypic characterisation of Familial Mediterranean Fever patients harboring variants of uncertain significance. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1695-1701.	0.9	1
13	Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 297-308.	0.9	11
14	Patient characteristics and minimal disease activity in psoriatic arthritis: a transcontinental comparison. <i>Clinical Rheumatology</i> , 2021, 40, 3169-3174.	2.2	2
15	Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 359-373.	1.8	24
16	Imaging modalities used in diagnosis and follow-up of patients with Takayasuâ€™s arteritis. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 224-230.	0.9	5
17	Punched-out erosions in sacroiliac joints. <i>Clinical Rheumatology</i> , 2021, 40, 3859-3860.	2.2	0
18	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 651715.	4.8	15

#	ARTICLE	IF	CITATIONS
19	Predictors of mortality in rheumatoid arthritis-associated lung disease: A retrospective study on ten years. <i>Joint Bone Spine</i> , 2021, 88, 105133.	1.6	11
20	Vasculitis during certolizumab pegol and secukinumab treatment: Report of two cases. <i>Dermatologic Therapy</i> , 2021, 34, e15007.	1.7	4
21	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. <i>Rheumatology International</i> , 2021, 41, 1915-1924.	3.0	1
22	Buddâ€™Chiari syndrome in Behçetâ€™s disease: a retrospective multicenter study. <i>Clinical Rheumatology</i> , 2021, , 1.	2.2	7
23	c-ANCA positivity in a patient with relapsing polychondritis: Co-incidence or not? A case and review of the literature. <i>Ulusal Romatoloji Dergisi</i> , 2021, 13, 88-90.	0.0	0
24	Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results. <i>American Journal of Ophthalmology</i> , 2021, 228, 58-64.	3.3	10
25	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1615-1623.	0.9	6
26	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 532-536.	0.8	0
27	Biological and targeted-synthetic disease-modifying anti-rheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: real-life TReasure prospective data. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 852-858.	0.8	1
28	Disease activity at the entheses and joints are correlated in psoriatic arthritis when explored with ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	1
29	Is the impact of biologic agents in enteropathic spondylitis different from other spondylitis? Real life data from the HUR-BIO Registry. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	0
30	Can we predict transition from psoriasis to psoriatic arthritis?. <i>Ulusal Romatoloji Dergisi</i> , 2021, 13, 121-128.	0.0	0
31	The influence of obesity on biological agents treatment response in psoriatic arthritis: HUR-BIO real life results. <i>Ulusal Romatoloji Dergisi</i> , 2021, 13, 107-115.	0.0	0
32	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 532-536.	0.8	8
33	Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease. <i>Arthritis Care and Research</i> , 2020, 72, 63-68.	3.4	35
34	Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study. <i>Rheumatology International</i> , 2020, 40, 41-48.	3.0	45
35	Familial Mediterranean fever-associated infertility and underlying factors. <i>Clinical Rheumatology</i> , 2020, 39, 255-261.	2.2	7
36	Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101512.	2.0	15

#	ARTICLE	IF	CITATIONS
37	Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. Turkish Journal of Medical Sciences, 2020, 50, 1337-1343.	0.9	13
38	Large joint and lower extremity involvement have higher impact on disease outcomes in oligoarticular psoriatic arthritis. International Journal of Rheumatic Diseases, 2020, 23, 1094-1099.	1.9	0
39	Anti-interleukin-6 (tocilizumab) therapy in Takayasu's arteritis: real-life experience. Turkish Journal of Medical Sciences, 2020, 50, 31-36.	0.9	4
40	Avascular necrosis less frequently found in systemic lupus erythematosus patients with the use of alternate day corticosteroid. Turkish Journal of Medical Sciences, 2020, 50, 219-224.	0.9	4
41	Current Smoking Is Increased in Axial Psoriatic Arthritis and Radiographic Sacroiliitis. Journal of Rheumatology, 2020, 47, 1354-1358.	2.0	6
42	Pregnancy outcomes in partners of male ankylosing spondylitis patients treated with anti-tumour necrosis factor- $\alpha$ biologics: real-life results from a single-centre cross-sectional study. Rheumatology International, 2020, 40, 1501-1507.	3.0	2
43	Temporomandibular disorders in ankylosing spondylitis: a cross-sectional, monocentric study. Rheumatology International, 2020, 40, 933-940.	3.0	6
44	Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry. European Journal of Rheumatology, 2020, 7, 64-67.	0.6	0
45	The evaluation of rheumatoid arthritis patients with knee and hip prosthesis: HURBIO biological registry. Ulusal Romatoloji Dergisi, 2020, 12, 39-44.	0.0	0
46	Evaluation of relationship between peripheral neuropathy and digital ulcer formation in patients with systemic sclerosis. Ulusal Romatoloji Dergisi, 2020, 12, 76-82.	0.0	0
47	Predictors of drug retention and treatment response in axial spondyloarthritis patients treated with certolizumab: real-life results from the HURBIO registry. Clinical and Experimental Rheumatology, 2020, 38, 609-614.	0.8	0
48	Factors associated with damage in patients with familial Mediterranean fever. Clinical and Experimental Rheumatology, 2020, 38 Suppl 127, 42-48.	0.8	2
49	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 85-94.	0.8	2
50	Proposal for a simple algorithm to differentiate adult-onset Still's disease with other fever of unknown origin causes: a longitudinal prospective study. Clinical Rheumatology, 2019, 38, 1699-1706.	2.2	18
51	Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry. Clinical Rheumatology, 2019, 38, 1187-1192.	2.2	6
52	The distribution of MEFV mutations in Turkish FMF patients: multicenter study representing results of Anatolia. Turkish Journal of Medical Sciences, 2019, 49, 472-477.	0.9	23
53	Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia. Rheumatology International, 2019, 39, 1045-1051.	3.0	4
54	Abnormal retinal microvasculature found in active rheumatoid arthritis: a different perspective of microvascular health. Turkish Journal of Medical Sciences, 2019, 49, 20-26.	0.9	4

#	ARTICLE	IF	CITATIONS
55	Two cases of glutaric aciduria type II: how to differentiate from inflammatory myopathies?. <i>Acta Clinica Belgica</i> , 2019, 74, 451-455.	1.2	2
56	Exon 2: Is it the good police in familial mediterranean fever?. <i>European Journal of Rheumatology</i> , 2019, 6, 33-36.	0.6	10
57	Comparison of Diagnostic Subgroup Survivals of Patients Who Admitted for Fever of Unknown Etiology Evaluation: Long-term Results of Single-centre, Prospective Study. <i>Flora: the Journal of Infectious Diseases and Clinical Microbiology = Infeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Dergisi</i> , 2019, 24, 199-206.	0.1	0
58	What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 808-812.	0.8	3
59	Evaluation of Vitamin B12 Deficiency and Associated Factors in Patients With Systemic Sclerosis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 250-254.	0.9	8
60	What does evidence-based medicine tell us about treatments for different subtypes of psoriatic arthritis? A systematic literature review on randomized controlled trials. <i>Rheumatology Advances in Practice</i> , 2018, 2, rlx019.	0.7	7
61	Comparison of early versus late onset familial Mediterranean fever. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 880-884.	1.9	25
62	Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients. <i>Arthritis Care and Research</i> , 2018, 70, 1090-1094.	3.4	48
63	Is the PET/CT first choice for differential diagnosis of fever of FUO/IUO?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e82-e82.	0.9	2
64	Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis. <i>Biomolecules</i> , 2018, 8, 136.	4.0	9
65	Methodology of a new inflammatory arthritis registry: TReasure. <i>Turkish Journal of Medical Sciences</i> , 2018, 48, 856-861.	0.9	7
66	Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor- $\alpha$ inhibitors in clinical practice. <i>Biologics: Targets and Therapy</i> , 2018, Volume 12, 1-9.	3.2	6
67	Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. <i>Clinical Rheumatology</i> , 2018, 37, 3443-3448.	2.2	24
68	Data of indirect immunofluorescence labeling of the mouse brain sections with sera from SLE and MS patients. <i>Data in Brief</i> , 2017, 15, 170-173.	1.0	0
69	The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. <i>Rheumatology</i> , 2017, 56, 279-286.	1.9	29
70	Performances of inflammatory back pain criteria in axial psoriatic arthritis. <i>Rheumatology</i> , 2017, 56, 2031-2032.	1.9	14
71	Rare occupational cause of nasal septum perforation: Nickel exposure. <i>International Journal of Occupational Medicine and Environmental Health</i> , 2017, 30, 963-967.	1.3	6
72	Alteration of the microRNA expression profile in familial Mediterranean fever patients. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 108, 90-94.	0.8	13

#	ARTICLE	IF	CITATIONS
73	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	3.8	35
74	The Reporting of Patient-reported Outcomes in Studies of Patients with Rheumatoid Arthritis: A Systematic Review of 250 Articles. <i>Journal of Rheumatology</i> , 2016, 43, 1300-1305.	2.0	41
75	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	2.0	24
76	Fatigue in psoriatic arthritis—A cross-sectional study of 246 patients from 13 countries. <i>Joint Bone Spine</i> , 2016, 83, 439-443.	1.6	47
77	Inflammatory bowel diseases and Takayasu's arteritis: coincidence or association?. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 814-818.	1.9	18
78	Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. <i>Journal of Autoimmunity</i> , 2016, 69, 59-63.	6.5	62
79	MEFV mutation frequency and effect on disease severity in ankylosing spondylitis. <i>Turkish Journal of Medical Sciences</i> , 2014, 44, 203-207.	0.9	13
80	Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. <i>Rheumatology</i> , 2014, 53, 741-745.	1.9	96
81	A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1012-1019.	0.9	314
82	Familial Mediterranean Fever and Central Nervous System Involvement. <i>Medicine (United States)</i> , 2010, 89, 75-84.	1.0	40
83	Factors Affecting the Sexual Satisfaction of Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. <i>Sexuality and Disability</i> , 2010, 28, 223-232.	1.0	24
84	Increased serum vitamin B12 levels are associated with adult-onset Still's disease with reactive macrophage activation syndrome. <i>Joint Bone Spine</i> , 2010, 77, 131-134.	1.6	16
85	Comment on: Monitoring Achilles enthesitis in ankylosing spondylitis during TNF- $\alpha$ antagonist therapy: an ultrasound study: reply. <i>Rheumatology</i> , 2010, 49, 1419-1420.	1.9	0
86	Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 103-108.	1.7	3
87	Accurate diagnosis of acute abdomen in FMF and acute appendicitis patients: how can we use procalcitonin?. <i>Clinical Rheumatology</i> , 2007, 26, 2059-2062.	2.2	20
88	Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. <i>Journal of Rheumatology</i> , 2007, 34, 1540-4.	2.0	53
89	Rubinstein-Taybi syndrome and familial Mediterranean fever in a single patient: two distinct genetic diseases located on chromosome 16p13.3. <i>Journal of the National Medical Association</i> , 2006, 98, 1692-3.	0.8	4
90	Conventional Synthetic Dmards in Psoriatic Arthritis: Changing Practice in Biologic Era; Real-Life Results from HURBIO-PsA Registry. <i>Acta Medica</i> , 0, , 1-7.	0.2	0

#	ARTICLE	IF	CITATIONS
91	Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: Treasure real-life data. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.8	6
92	Evaluation of Intravenous Immunoglobulin G treatment in Outpatients Rheumatology Practice. <i>Acta Medica</i> , 0, , 1-8.	0.2	1